Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Review
. 2017 Mar;24(3):130-133.
doi: 10.1038/cgt.2016.58. Epub 2017 Feb 10.

Current status of immunotherapy for gastrointestinal stromal tumor

Y Tan  1 , J C Trent  2   3 , B A Wilky  2   3 , D A Kerr  1   3 , A E Rosenberg  1   3
Affiliations
Review

Current status of immunotherapy for gastrointestinal stromal tumor

Y Tan et al. Cancer Gene Ther. 2017 Mar.

Abstract

Gastrointestinal stromal tumors (GIST) contain tumor-infiltrating immune cells and their presence provides an opportunity and rationale for developing effective forms of immunotherapy. The types of tumor-infiltrating inflammatory cells and relevant immune checkpoint inhibitors are the focus of active investigation. The most numerous tumor-infiltrating inflammatory cells are tumor-associated macrophages (TAMs) and CD3+ T cells VSports手机版. Studies have shown that patients with GISTs that harbor increased numbers of CD3+ T cells have better outcomes. However, the clinical behavior of GIST has not been shown to correlate with the number of TAMs. The biological significance of other less frequent tumor-infiltrating immune cells including tumor-infiltrating neurtrophils (TINs), natural killer cells (NKs), B cells, dendritic cells (DCs) remains unclear. The immune checkpoint inhibitors CTLA-4, PD1/PDL1 and TIM3/galectin-9 are molecules that can be targeted by synthesized antibodies. Clinical and pre-clinical trials using this approach against immune checkpoint inhibitors, anti-KIT antibody and the generation of chimeric antigen receptor (CAR) T-cells have shown promising results. The treatment of GIST with immunotherapy is complex and evolving; this article reviews its current status for patients with GISTs. .

PubMed Disclaimer

VSports app下载 - References

    1. Oncoimmunology. 2015 Feb 3;4(5):e1002729 - PubMed
    1. Nat Med. 2011 Aug 28;17(9):1094-100 - "V体育ios版" PubMed
    1. Cancer Immunol Immunother. 2012 Jul;61(7):1113-24 - PubMed
    1. Expert Rev Anticancer Ther. 2014 Dec;14(12):1445-59 - PubMed
    1. Int J Cancer. 2010 Aug 15;127(4):899-909 - PubMed

Publication types

V体育ios版 - MeSH terms